D. Boral Capital Reiterates Buy Rating for OS Therapies (NYSE:OSTX)

OS Therapies (NYSE:OSTX)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a research note issued to investors on Thursday,Benzinga reports. They currently have a $20.00 price target on the stock.

Separately, Maxim Group boosted their price target on shares of OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, January 16th.

OS Therapies Stock Performance

OSTX opened at $1.86 on Thursday. The stock’s 50 day simple moving average is $3.36 and its 200-day simple moving average is $3.15. OS Therapies has a 1 year low of $1.58 and a 1 year high of $7.00.

Insider Activity

In related news, major shareholder Shalom Auerbach sold 100,000 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $2.84, for a total value of $284,000.00. Following the sale, the insider now owns 2,431,211 shares of the company’s stock, valued at $6,904,639.24. The trade was a 3.95 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Institutional Inflows and Outflows

An institutional investor recently raised its position in OS Therapies stock. CM Management LLC lifted its position in OS Therapies Inc (NYSE:OSTX) by 120.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 110,044 shares of the company’s stock after purchasing an additional 60,044 shares during the quarter. CM Management LLC owned 0.51% of OS Therapies worth $471,000 at the end of the most recent reporting period.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.